Copyright investors
BioLife Solutions (BLFS) saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 78 to 81. IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database. Over 100 years of market history reveals that the best stocks typically have an RS Rating north of 80 as they launch their biggest price moves. BioLife Solutions broke out earlier, but has fallen back below the prior 27.52 entry from a cup with handle. If a stock you're watching clears a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new consolidation and breakout. Also keep in mind that the most recent consolidation is a later-stage base, and those involve more risk. BioLife Solutions reported 0% earnings growth in its most recent report. Revenue increased 29%. The next quarterly numbers are expected on or around Nov. 6. The company holds the No. 12 rank among its peers in the Medical-Products industry group. Axogen (AXGN), TransMedics Group (TMDX) and Insulet (PODD) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
